Mirion Technologies Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved. No questions were raised during the Q&A, and risks related to forward-looking statements were noted.
-
Orders and backlog surged on strong nuclear and medical segment growth, with Paragon and Certrec acquisitions driving early synergies. Revenue and adjusted EBITDA rose year-over-year, and guidance remains confident for 2026, with margin expansion and robust nuclear demand expected.
-
Nuclear power drives nearly half of revenue, with strong growth in SMRs, international projects, and recurring installed base business. Margin expansion, robust backlog, and AI-driven productivity are key themes, while medical and nuclear medicine segments show continued growth potential.
Fiscal Year 2025
-
Record orders and strong growth in nuclear power and medicine drove 2025 results, with revenue up 7.5% and Adjusted EBITDA up 12%. 2026 guidance calls for 22%-24% revenue growth, margin expansion, and robust free cash flow, supported by recent acquisitions and a growing project pipeline.
-
Q3 revenue grew 8% year-over-year, led by strong nuclear power and medical segment performance. Adjusted EBITDA rose 15%, and free cash flow guidance was raised. Acquisitions and robust order growth position the business for continued momentum.
-
The acquisition expands nuclear market reach, especially in the U.S. and SMR segments, and is expected to be accretive to earnings in the first year. $10 million in annualized synergies are targeted, with integration over 18 months and a focus on recurring revenue and long-term growth.
-
Q2 2025 delivered strong revenue and EBITDA growth, driven by both nuclear and medical segments, with raised full-year guidance reflecting robust nuclear power demand and successful M&A. The Certrec acquisition and new digital platforms position the company for continued growth.
-
Q1 delivered strong organic growth, margin expansion, and robust order intake, especially in nuclear power. Guidance for 2025 was reaffirmed and raised for revenue, with tariff risks mitigated and a strategic software acquisition completed.
-
A global leader in ionizing radiation solutions, the company leverages its dominance in nuclear and medical markets to drive recurring revenue and capitalize on long-term trends in nuclear power and cancer care. Financial targets focus on free cash flow growth and disciplined M&A.
-
The company is positioned as a leader in ionizing radiation detection, with strong growth driven by nuclear power and healthcare trends. Margin expansion is expected through operational leverage and procurement, while a robust pipeline of large orders and renewed M&A activity support future growth. Capital allocation focuses on both organic and inorganic opportunities.
Fiscal Year 2024
-
Record 2024 results with double-digit growth in revenue and EBITDA, margin expansion, and strong cash flow. 2025 guidance calls for continued growth, margin improvement, and higher free cash flow, supported by a robust backlog and favorable nuclear and medical market trends.
-
Industry tailwinds in nuclear and medical segments are driving strong growth, with robust recurring revenue, expanding new build pipelines, and higher-margin opportunities in SMRs. Long-term targets include 6%-8% organic growth, 30% EBITDA margin, and significant free cash flow expansion.
-
Raised organic growth guidance to 6%-8% and committed to 30% EBITDA margins by 2028, driven by strong nuclear and medical market trends, digitalization, and innovation. Strategic partnerships, recurring revenue, and a robust M&A pipeline support long-term growth.
-
Q3 revenue grew 8% year-over-year, with margin expansion and strong performance in both nuclear and medical segments. Guidance for full-year adjusted EBITDA and EPS remains unchanged, while leverage continues to decline and the bid pipeline is robust, especially in nuclear power.
-
Q2 saw 5% revenue and 10.2% adjusted EBITDA growth, with margin expansion and strong Nuclear and Medical segment performance. Guidance was raised for adjusted EBITDA, and a major EDF partnership was signed, while international Medical headwinds are expected to ease in 2025.
-
A global leader in radiation detection, the firm leverages innovation and a strong market position across industrial and medical segments. The medical segment is rapidly growing, while nuclear power trends and new builds, especially in Europe and Asia, support long-term growth.